相关实验视频

Updated: May 10, 2026

Implantation of the Syncardia Total Artificial Heart

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

跨导管大动脉置换后永久心脏起器植入的风险:哪些因素最相关?

Akash Batta¹, Juniali Hatwal²

¹Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab, India. akashbatta02@gmail.com.

World journal of cardiology

|March 8, 2024

概括

过导管大动脉置换 (TAVR) 可能需要永久起器 (PPM). 基线QRS持续时间超过120毫秒或糖尿病患者在TAVR后需要PPM的几率更高.

科学领域:

心脏病学心脏病学
干预心脏病学干预心脏病学
心脏电生理学心脏电生理学

背景情况:

过导管大动脉置换 (TAVR) 越来越多地用于严重的症状大动脉狭窄,包括低风险患者.
在TAVR后需要永久性起器 (PPM) 是一个常见的和重要的临床挑战.
鉴定TAVR后传导异常的预测因素对于患者管理至关重要.

研究的目的:

为了确定与需要永久心脏起器植入的需要相关的风险因素,通过导管的大动脉替换后.
评估基线心电图学特征与TAVR后导电块之间的关联.
探索影响TAVR后PPM要求的人口和临床因素.

主要方法:

对接受TAVR的患者进行回顾性分析.
基线人口统计,心电图和程序数据的评估.
后勤回归建模以确定PPM需求的预测因素.

主要成果:

与不需要PPM的患者相比,在TAVR后需要PPM的患者在基线QRS持续时间>120毫秒的患病率显著更高.
糖尿病被确定为另一个与TAVR后PPM植入率增加相关的重要危险因素.
长时间的QRS持续时间成为了需要PPM的先进导电块的强有力的独立预测因素.

结论:

基线QRS持续时间> 120毫秒是TAVR后永久心脏起器植入的关键预测指标.
糖尿病与TAVR后需要PPM的可能性更高.
使用基线心电图和临床因素进行风险分层可以帮助预测TAVR后的PPM需求.

关键词:

糖尿病是一种糖尿病.电生理学变量电生理学变量永久性起器是一种心脏起器.QRS的持续时间通过导管更换大动脉门.

更多相关视频

Implantation of Total Artificial Heart in Congenital Heart Disease

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

相关概念视频

Mitral Valve Prolapse II: Assessment and Management

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.

Mitral Stenosis III: Medical Management

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...

Aortic Regurgitation I: Introduction

Aortic Regurgitation I: Introduction

IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...

Aortic Regurgitation III: Medical Management

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...